Skip to main content
SpringerLink
Log in

Mild Cognitive Impairment – MCI

Ist die MCI ein klinisches Vorstadium der Alzheimerdemenz?

  • Aktuelles
  • Published:
focus neurogeriatrie

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Referenzen

  • Andlin-Sobocki P, Jonsson B, Wittchen HU, Olesen J. Cost of disorders of the brain in Europe. Eur J Neurol 2005,12 Suppl 1:1–27

    Article  PubMed  Google Scholar 

  • Jonsson L, Berr C. Cost of dementia in Europe. Eur J Neurol 2005,12 Suppl 1:50–53

    Article  PubMed  Google Scholar 

  • DeCarli C. Mild cognitive impairment: prevalence, prognosis, aetiology, and treatment. Lancet Neurol 2003,2:15–21

    Article  PubMed  Google Scholar 

  • Kral VA. Senescent forgetfulness: benign and malignant. Can Med Assoc J 1962,86:257–260

    PubMed  CAS  Google Scholar 

  • Crook T, Bartus R, Ferries S. Age-associated memory impairment: proposed diagnostic criteria and measures of change. Dev Neuropsychol 1986,2:295–306

    Google Scholar 

  • Blackford RC, La Rue A. Criteria for diagnosing age-associated memory impairment: proposed improvements in the field. Dev Neuropsychol 1989,5:295–306

    Article  Google Scholar 

  • Levy R. Aging-associated cognitive decline. Working Party of the International Psychogeriatric Association in collaboration with the World Health Organization. Int Psychogeriatr 1994,6:63–68

    Article  PubMed  CAS  Google Scholar 

  • Graham JE, Rockwood K, Beattie BL, Eastwood R, Gauthier S, Tuokko H, McDowell I. Prevalence and severity of cognitive impairment with and without dementia in an elderly population. Lancet 1997,349:1793–1796

    Article  PubMed  CAS  Google Scholar 

  • Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999,56:303–308

    Article  PubMed  CAS  Google Scholar 

  • Goldman WP, Morris JC. Evidence that age-associated memory impairment is not a normal variant of aging. Alzheimer Dis Assoc Disord 2001,15:72–79

    Article  PubMed  CAS  Google Scholar 

  • Petersen RC, Smith GE, Waring SC, Ivnik RJ, Kokmen E, Tangelos EG. Aging, memory, and mild cognitive impairment. Int Psychogeriatr 1997,9 Suppl 1:65–69

    Article  PubMed  Google Scholar 

  • Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med 2004,256:183–194

    Article  PubMed  CAS  Google Scholar 

  • Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, et al. Current concepts in mild cognitive impairment. Arch Neurol 2001,58:1985–1992

    Article  PubMed  CAS  Google Scholar 

  • Gauthier S, Reisberg B, Zaudig M, Petersen RC, Ritchie K, Broich K, et al. Mild cognitive impairment. Lancet 2006,367:1262–1270

    Article  PubMed  Google Scholar 

  • Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, et al. Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med 2004,256:240–246

    Article  PubMed  CAS  Google Scholar 

  • Artero S, Tierney MC, Touchon J, Ritchie K. Prediction of transition from cognitive impairment to senile dementia: a prospective, longitudinal study. Acta Psychiatr Scand 2003,107:390–393

    Article  PubMed  CAS  Google Scholar 

  • Chen P, Ratcliff G, Belle SH, Cauley JA, DeKosky ST, Ganguli M. Cognitive tests that best discriminate between presymptomatic AD and those who remain nondemented. Neurology 2000,55:1847–1853

    PubMed  CAS  Google Scholar 

  • Carr DB, Gray S, Baty J, Morris JC. The value of informant versus individual’s complaints of memory impairment in early dementia. Neurology 2000,55:1724–1726

    PubMed  CAS  Google Scholar 

  • Andreasen N, Sjogren M, Blennow K. CSF markers for Alzheimer’s disease: total tau, phospho-tau and Abeta42. World J Biol Psychiatry 2003,4:147–155

    Article  PubMed  Google Scholar 

  • Blennow K, Hampel H. CSF markers for incipient Alzheimer’s disease. Lancet Neurol 2003,2:605–613

    Article  PubMed  CAS  Google Scholar 

  • Fellgiebel A, Siessmeier T, Scheurich A, Winterer G, Bartenstein P, Schmidt LG, Muller MJ. Association of elevated phospho-tau levels with Alzheimer-typical 18F-fluoro-2-deoxy-D-glucose positron emission tomography findings in patients with mild cognitive impairment. Biol Psychiatry 2004,56:279–283

    Article  PubMed  CAS  Google Scholar 

  • de Leon MJ, DeSanti S, Zinkowski R, Mehta PD, Pratico D, Segal S, et al. Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. Neurobiol Aging 2006,27:394–401

    Article  PubMed  CAS  Google Scholar 

  • Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006,5:228–234

    Article  PubMed  CAS  Google Scholar 

  • Herukka SK, Hallikainen M, Soininen H, Pirttila T. CSF Abeta42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment. Neurology 2005,64:1294–1297

    PubMed  CAS  Google Scholar 

  • Parnetti L, Lanari A, Silvestrelli G, Saggese E, Reboldi P. Diagnosing prodromal Alzheimer’s disease: role of CSF biochemical markers. Mech Ageing Dev 2006,127:129–132

    Article  PubMed  CAS  Google Scholar 

  • Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 2006,59:512–519

    Article  PubMed  CAS  Google Scholar 

  • Drzezga A, Grimmer T, Riemenschneider M, Lautenschlager N, Siebner H, Alexopoulus P, et al. Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET. J Nucl Med 2005,46:1625–1632

    PubMed  CAS  Google Scholar 

  • Reiman EM, Caselli RJ, Yun LS, Chen K, Bandy D, Minoshima S, et al. Preclinical evidence of Alzheimer’s disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med 1996,334:752–758

    Article  PubMed  CAS  Google Scholar 

  • Fleisher A, Grundman M, Jack CR, Jr., Petersen RC, Taylor C, Kim HT, et al. Sex, apolipoprotein E epsilon 4 status, and hippocampal volume in mild cognitive impairment. Arch Neurol 2005,62:953–957

    Article  PubMed  Google Scholar 

  • De Santi S, de Leon MJ, Rusinek H, Convit A, Tarshish CY, Roche A, et al. Hippocampal formation glucose metabolism and volume losses in MCI and AD. Neurobiol Aging 2001,22:529–539

    Article  PubMed  CAS  Google Scholar 

  • deToledo-Morrell L, Stoub TR, Bulgakova M, Wilson RS, Bennett DA, Leurgans S, et al. MRI-derived entorhinal volume is a good predictor of conversion from MCI to AD. Neurobiol Aging 2004,25:1197–1203

    Article  PubMed  Google Scholar 

  • Korf ES, Wahlund LO, Visser PJ, Scheltens P. Medial temporal lobe atrophy on MRI predicts dementia in patients with mild cognitive impairment. Neurology 2004,63:94–100

    PubMed  Google Scholar 

  • Stoub TR, Bulgakova M, Leurgans S, Bennett DA, Fleischman D, Turner DA, deToledo-Morrell L. MRI predictors of risk of incident Alzheimer disease: a longitudinal study. Neurology 2005,64:1520–1524

    Article  PubMed  CAS  Google Scholar 

  • Szelies B, Grond M, Herholz K, Kessler J, Wullen T, Heiss WD. Quantitative EEG mapping and PET in Alzheimer’s disease. J Neurol Sci 1992,110:46–56

    Article  PubMed  CAS  Google Scholar 

  • Koenig T, Prichep L, Dierks T, Hubl D, Wahlund LO, John ER, Jelic V. Decreased EEG synchronization in Alzheimer’s disease and mild cognitive impairment. Neurobiol Aging 2005,26:165–171

    Article  PubMed  CAS  Google Scholar 

  • Modrego PJ, Fayed N, Pina MA. Conversion from mild cognitive impairment to probable Alzheimer’s disease predicted by brain magnetic resonance spectroscopy. Am J Psychiatry 2005,162:667–675

    Article  PubMed  Google Scholar 

  • Herholz K, Herscovitch P, Heiss WD. NeuroPET – Positron Emission Tomography in Neuroscience and Clinical Neurology. Berlin: Springer; 2004

    Google Scholar 

  • Herholz K, Salmon E, Perani D, Baron JC, Holthoff V, Frolich L, et al. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage 2002,17:302–316

    Article  PubMed  CAS  Google Scholar 

  • Anchisi D, Borroni B, Franceschi M, Kerrouche N, Kalbe E, Beuthien-Beumann B, et al. Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease. Arch Neurol 2005,62:1728–1733

    Article  PubMed  Google Scholar 

  • Chetelat G, Desgranges B, de la Sayette V, Viader F, Eustache F, Baron JC. Mild cognitive impairment: Can FDG-PET predict who is to rapidly convert to Alzheimer’s disease? Neurology 2003,60:1374–1377

    PubMed  CAS  Google Scholar 

  • de Leon MJ, Convit A, Wolf OT, Tarshish CY, DeSanti S, Rusinek H, et al. Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/positron-emission tomography (FDG/PET). Proc Natl Acad Sci U S A 2001,98:10966–10971

    Article  PubMed  CAS  Google Scholar 

  • Drzezga A, Lautenschlager N, Siebner H, Riemenschneider M, Willoch F, Minoshima S, et al. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer’s disease: a PET follow-up study. Eur J Nucl Med Mol Imaging 2003,30:1104–1113

    Article  PubMed  Google Scholar 

  • Herholz K, Nordberg A, Salmon E, Perani D, Kessler J, Mielke R, et al. Impairment of neocortical metabolism predicts progression in Alzheimer’s disease. Dement Geriatr Cogn Disord 1999,10:494–504

    Article  PubMed  CAS  Google Scholar 

  • Jagust W, Gitcho A, Sun F, Kuczynski B, Mungas D, Haan M. Brain imaging evidence of preclinical Alzheimer’s disease in normal aging. Ann Neurol 2006,59:673–681

    Article  PubMed  Google Scholar 

  • Herholz K, Weisenbach S, Zundorf G, Lenz O, Schroder H, Bauer B, et al. In vivo study of acetylcholine esterase in basal forebrain, amygdala, and cortex in mild to moderate Alzheimer disease. Neuroimage 2004,21:136–143

    Article  PubMed  CAS  Google Scholar 

  • Herholz K, Weisenbach S, Kalbe E, Diederich NJ, Heiss WD. Cerebral acetylcholine esterase activity in mild cognitive impairment. Neuroreport 2005,16:1431–1434

    Article  PubMed  CAS  Google Scholar 

  • Mathis CA, Wang Y, Holt DP, Huang GF, Debnath ML, Klunk WE. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem 2003,46:2740–2754

    Article  PubMed  CAS  Google Scholar 

  • Smid LM, Vovko TD, Popovic M, Petric A, Kepe V, Barrio JR, et al. The 2,6-disubstituted naphthalene derivative FDDNP labeling reliably predicts Congo red birefringence of protein deposits in brain sections of selected human neurodegenerative diseases. Brain Pathol 2006,16:124–130

    Article  PubMed  CAS  Google Scholar 

  • Huddleston DE, Small SA. Technology insight: imaging amyloid plaques in the living brain with positron emission tomography and MRI. Nat Clin Pract Neurol 2005,1:96–105

    Article  PubMed  Google Scholar 

  • Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann Neurol 2004,55:306–319

    Article  PubMed  CAS  Google Scholar 

  • Mintun MA, Larossa GN, Sheline YI, Dence CS, Lee SY, Mach RH, et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 2006,67:446–452

    Article  PubMed  CAS  Google Scholar 

  • Price JC, Klunk WE, Lopresti BJ, Lu X, Hoge JA, Ziolko SK, et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab 2005,25:1528–1547

    Article  PubMed  CAS  Google Scholar 

  • Petersen RC, Morris JC. Mild cognitive impairment as a clinical entity and treatment target. Arch Neurol 2005,62:1160–1163; discussion 1167

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Max-Planck-Inst. f. neurologische Forschung, Köln

    Cathleen Hänse & Wolf-Dieter Heiss

Authors
  1. Cathleen Hänse
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wolf-Dieter Heiss
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hänse, C., Heiss, WD. Mild Cognitive Impairment – MCI. focus neurogeriatrie 1, 9–12 (2007). https://doi.org/10.1007/s12151-007-0025-2

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12151-007-0025-2

Search

Navigation